TITLE:
Anti-Hypertensive Prescription and Cost Patterns in an Outpatient Department of a Teaching Hospital in Lagos State Nigeria
AUTHORS:
Akin Osibogun, Tochi Joy Okwor
KEYWORDS:
Hypertension; Prescription Patterns; Co-Morbidity; Cost; Nigeria
JOURNAL NAME:
Open Journal of Preventive Medicine,
Vol.4 No.4,
April
3,
2014
ABSTRACT:
Introduction: Hypertension is a
public health problem with a high prevalence in Nigeria. The cost of
prescription medications is thought to be a barrier for many patients to access
the healthcare they need. This study was aimed at identifying associated
co-morbid conditions, the prescribing patterns and cost of prescription for the
treatment of hypertension in an outpatient clinic at Lagos University Teaching
Hospital. Materials and Methods: A cross sectional study was carried out. A
total of 147 prescriptions were obtained from the case notes of patients
treated at the LUTH outpatient
department between February 2012 and August 2012. For each prescription, the
number of drugs, the class and combinations of antihypertensives were recorded.
The monthly cost of a 30-day anti-hypertensive supply based on the recommended
daily dose was calculated. Results: The mean age of the patients was 54(+/-14)
years and of the 147 prescriptions, 77(52.4%) was for females and 70(47.6%) was
for males. The mean systolic blood pressure was 141.6 mmHg (+/-20.5SD) and mean
diastolic blood pressure was 86.5 mmHg (+/-13.3SD). Of the 147 prescriptions, 112(76.2%) were for patients with
co-morbidities. The frequency of prescription of the various classes of anti
hypertensives are; diuretics 117(79.6%), angiotensin receptor blockers
78(53.1%), angiotensin converting enzyme inhibitors 65(44.2%), calcium channel
blockers 65 (44.2%) beta
blockers 54(36.7%) and centrally acting agents 12(8.2%). Average cost per month
was =N=6611.47 (US$44). There was a statistically significant association
between co morbid conditions and
high cost of prescriptions with 73.7% of those with diabetes and 63.2% of those
with renal disease having cost of prescriptions within the high cost group (p